BNP Paribas Financial Markets’s Kezar Life Sciences KZR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-89
| Closed | -$660 | – | 6059 |
|
|
2026
Q1 | $660 | Hold |
89
| – | – | ﹤0.01% | 5513 |
|
|
2025
Q4 | $560 | Sell |
89
-7
| -7% | -$41 | ﹤0.01% | 5470 |
|
|
2025
Q3 | $374 | Hold |
96
| – | – | ﹤0.01% | 5336 |
|
|
2025
Q2 | $440 | Hold |
96
| – | – | ﹤0.01% | 5232 |
|
|
2025
Q1 | $468 | Sell |
96
-13
| -12% | -$79 | ﹤0.01% | 5145 |
|
|
2024
Q4 | $732 | Buy |
+109
| New | +$812 | ﹤0.01% | 5125 |
|
|
2024
Q3 | – | Sell |
-44,372
| Closed | -$266K | – | 4195 |
|
|
2024
Q2 | $266K | Buy |
44,372
+17,029
| +62% | +$129K | ﹤0.01% | 2986 |
|
|
2024
Q1 | $247K | Buy |
27,343
+7,154
| +35% | +$65.2K | ﹤0.01% | 3186 |
|
|
2023
Q4 | $191K | Buy |
20,189
+11,809
| +141% | +$104K | ﹤0.01% | 3234 |
|
|
2023
Q3 | $99.7K | Buy |
8,380
+6,651
| +385% | +$118K | ﹤0.01% | 3327 |
|
|
2023
Q2 | $42.4K | Sell |
1,729
-8,526
| -83% | -$222K | ﹤0.01% | 3512 |
|
|
2023
Q1 | $321K | Buy |
10,255
+3,116
| +44% | +$180K | ﹤0.01% | 2954 |
|
|
2022
Q4 | $503K | Sell |
7,139
-4,316
| -38% | -$320K | ﹤0.01% | 2574 |
|
|
2022
Q3 | $986K | Buy |
11,455
+9,807
| +595% | +$953K | ﹤0.01% | 2498 |
|
|
2022
Q2 | $136K | Buy |
1,648
+1,197
| +265% | +$106K | ﹤0.01% | 3244 |
|
|
2022
Q1 | $74.9K | Sell |
451
-902
| -67% | -$129K | ﹤0.01% | 3447 |
|
|
2021
Q4 | $226K | Buy |
1,353
+599
| +79% | +$67.6K | ﹤0.01% | 3352 |
|
|
2021
Q3 | $65.1K | Buy |
754
+437
| +138% | +$28.9K | ﹤0.01% | 3442 |
|
|
2021
Q2 | $17.2K | Sell |
317
-925
| -74% | -$52.5K | ﹤0.01% | 3569 |
|
|
2021
Q1 | $74K | Buy |
1,242
+737
| +146% | +$43.1K | ﹤0.01% | 3485 |
|
|
2020
Q4 | $26.4K | Sell |
505
-168
| -25% | -$9.35K | ﹤0.01% | 3789 |
|
|
2020
Q3 | $32.6K | Buy |
673
+564
| +517% | +$27K | ﹤0.01% | 3656 |
|
|
2020
Q2 | $5.64K | Sell |
109
-806
| -88% | -$40.7K | ﹤0.01% | 3958 |
|
|
2020
Q1 | $39.9K | Buy |
915
+545
| +147% | +$22.2K | ﹤0.01% | 3652 |
|
|
2019
Q4 | $14.8K | Buy |
370
+152
| +70% | +$4.68K | ﹤0.01% | 4070 |
|
|
2019
Q3 | $7.16K | Buy |
218
+2
| +0.9% | +$97 | ﹤0.01% | 4214 |
|
|
2019
Q2 | $16.7K | Sell |
216
-48
| -18% | -$7.46K | ﹤0.01% | 3959 |
|
|
2019
Q1 | $46.8K | Buy |
+264
| New | +$52K | ﹤0.01% | 3538 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 4259 |
|
BNP Paribas Financial Markets's KZR Position: Q2 2026 in Review
BNP Paribas Financial Markets sold out of Kezar Life Sciences (KZR) in Q2 2026, closing a stake of 89 shares — an estimated $660 sold.
BNP Paribas Financial Markets first reported a position in KZR in Q1 2019 and held it in 28 quarters. The position peaked at $986K in Q3 2022. 0 funds tracked by Wall St. Rank hold KZR as of Q2 2026.
- BNP Paribas Financial Markets reported no remaining Kezar Life Sciences position as of Q2 2026 after selling out during the quarter.
- BNP Paribas Financial Markets sold 89 Kezar Life Sciences shares in Q2 2026, an estimated $660.
- BNP Paribas Financial Markets first reported a position in Kezar Life Sciences in Q1 2019 and held it in 28 quarters.
- BNP Paribas Financial Markets's Kezar Life Sciences position peaked at $986K in Q3 2022.
- 0 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.